Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1505163

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he expects NICE's review of Evusheld to be concluded.
	tabling member constituency	North Durham
	tabling member printed	Mr Kevan Jones
	uin	47379
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>On 10 August 2022, the Department referred tixagevimab and cilgavimab (Evusheld) to the National Institute for Health and Care Excellence (NICE) to evaluate its clinical and cost effectiveness for preventing COVID-19. Between 29 July and 12 August, NICE consulted with stakeholders on the suggested remit, draft scope and list of consultees and commentators.</p><p>NICE has commenced this evaluation and currently expects to publish draft guidance in April 2023, with final guidance to follow in May 2023. In discussion with AstraZeneca, NICE is expediting the appraisal process by bringing forward the deadline for the manufacturer’s evidence submission.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 20/09/2022 14:34:16 answering member 4320 label Biography information for Robert Jenrick previous answer version 17716 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1438 label Biography information for Mr Kevan Jones

1505139

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nurses: Recruitment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he expects eligible post-graduate nurses to receive the £10,000 golden hello payment announced in May 2018.
	tabling member constituency	Kingston upon Hull East
	tabling member printed	Karl Turner
	uin	47512
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>In May 2018, we announced the intention to pay a ‘golden hello’ to nurses who started a postgraduate course in learning disability nursing, mental health nursing or district nursing in the 2018/19 academic year who subsequently qualified and were employed in these roles in the health and care sector.</p><p>The Government is considering the most effective way to administer and introduce any scheme to ensure it delivers on the original intent.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 20/09/2022 14:37:11 answering member 4320 label Biography information for Robert Jenrick previous answer version 17720 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4030 label Biography information for Karl Turner

1504776

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Temporary Employment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the total cost to NHS hospitals was of using (a) agency and (b) bank staff in each region in England in the 2021-22 financial year.
	tabling member constituency	Enfield North
	tabling member printed	Feryal Clark
	uin	47698
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>The information requested is not yet held in the format requested as the accounts for 2021/22 are currently being audited.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 20/09/2022 14:35:04 answering member 4320 label Biography information for Robert Jenrick previous answer version 17726 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4822 label Biography information for Feryal Clark

1504891

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Respiratory Syncytial Virus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, on what date he expects NHS England’s Palivizumab Expert Group to respond to the request from the JCVI to consider the eligibility of children with spinal muscular atrophy to receive the Palivizumab vaccination against respiratory syncytial virus.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	47662
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47663 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17723 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4769 label Biography information for Daisy Cooper

1504892

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Respiratory Syncytial Virus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to recommendations in the consensus statement of the 2017 International Conference on the Standards of Care on the use of Palivizumab for some categories of children with spinal muscular atrophy to protect from respiratory syncytial virus, if he will take steps to urgently review the eligibility criteria for the Palivizumab vaccine.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	47663
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>Respiratory syncytial virus (RSV) infection poses a serious risk for children with spinal muscular atrophy (SMA) with weakened respiratory muscles due to their condition. Following a letter from clinicians, the Joint Committee on Vaccination and Immunisation (JCVI) has requested that NHS England’s Palivizumab National Expert Group consider the eligibility of a sub-group of children with SMA to receive palivizumab vaccination this winter. This Group is preparing a briefing and on completion, it will meet and report the outcome of its discussion and recommendations to the JCVI. A specific date has yet to be confirmed.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson grouped question UIN 47662 question first answered 20/09/2022 14:29:09 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17724 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4769 label Biography information for Daisy Cooper

1505113

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to monitor the provision of free incontinence products across Integrated Care Boards; and what assessment he has made of the impact of the availability of those products on disabled people’s mobility and quality of life.
	tabling member constituency	Oxford East
	tabling member printed	Anneliese Dodds
	uin	47638
	answer	answer is ministerial correction date of answer 20/09/2022 answer text <p>No specific assessment has been made. However, general practitioners and incontinence clinics are expected to offer free incontinence products to all eligible patients following an assessment and diagnosis of incontinence issues. While there is no statutory requirement for the provision of pads for incontinence, all clinicians and integrated care boards are expected to follow the best practice in provision of incontinence products.</p> answering member constituency Sleaford and North Hykeham answering member printed Dr Caroline Johnson question first answered 20/09/2022 14:36:26 answering member 4592 label Biography information for Dr Caroline Johnson previous answer version 17722 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4657 label Biography information for Anneliese Dodds

1505070

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Protective Clothing: Storage
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, on how many occasions since 1 January 2022 has (a) he or (b) his predecessor received requests from the Chancellor of the Exchequer to discuss the cost of the storage of personal protective equipment.
	tabling member constituency	Ashton-under-Lyne
	tabling member printed	Angela Rayner
	uin	47556
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Department remains in regular contact with HM Treasury regarding the cost of storing personal protective equipment.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 16:07:09 answering member 4320 label Biography information for Robert Jenrick previous answer version 17721 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	4356 label Biography information for Angela Rayner

1504790

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the level of access to antiviral treatments for people who are acutely vulnerable to covid-19.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	47395
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>For patients whose immune system means they are at the highest risk from COVID-19 and who test positive for the virus, treatments can be accessed directly through COVID Medicine Delivery Units (CMDUs). Those patients at high risk of COVID-19 who are ineligible to access treatments via CMDUs can access antivirals via the PANORAMIC national study.</p><p>The Department and NHS England are monitoring the uptake of antiviral treatment against those digitally identified as eligible. In England, 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the date of symptom onset.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:24:35 answering member 4320 label Biography information for Robert Jenrick previous answer version 17717 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1506 label Biography information for Andrew Gwynne

1504791

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Monkeypox: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to accelerate resumption of the Monkeypox vaccination rollout.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	47396
	answer	answer is ministerial correction date of answer 31/10/2022 answer text <p>The UK Health Security Agency (UKHSA) procured over 150,000 doses of Monkeypox vaccines, with 70,000 vials arriving in the United Kingdom by September and a further 80,000 vials in October.</p><p> </p><p>The UKHSA has endorsed the use of ‘fractional dosing’, in which people aged 18 years old and over can be offered a 0.1 millilitre dose of the Jynneos smallpox vaccine, replacing the 0.5 millilitre dose typically administered. This will enable up to a five-fold increase in the number of people offered vaccination with the same level of effectiveness.  There has been no pause in the programme since it began.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 31/10/2022 17:40:50 answering member 4679 label Biography information for Neil O'Brien previous answer version 17718 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1506 label Biography information for Andrew Gwynne

1504818

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	47397
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.</p><p>We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:27:13 answering member 4320 label Biography information for Robert Jenrick previous answer version 17719 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1506 label Biography information for Andrew Gwynne